Interim results from a large multinational extension trial (Guardian TM2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

Interim results from a large multinational extension trial (Guardian TM2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

S. Lentz, C. L. Kempton, D. Janic, A. Savic, M. H. Cerqueira, M. C. Ozelo, M. Recht, J. Oldenburg, A. Tiede, T. Suzuki, I Matytsina, N. Zeuthen, E. Santagostino

Interim results from a large multinational extension trial (Guardian TM2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

S. Lentz, C. L. Kempton, D. Janic, A. Savic, M. H. Cerqueira, M. C. Ozelo, M. Recht, J. Oldenburg, A. Tiede, T. Suzuki, I Matytsina, N. Zeuthen, E. Santagostino


										

Interim results from a large multinational extension trial (Guardian TM2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

S. Lentz, C. L. Kempton, D. Janic, A. Savic, M. H. Cerqueira, M. C. Ozelo, M. Recht, J. Oldenburg, A. Tiede, T. Suzuki, I Matytsina, N. Zeuthen, E. Santagostino

    Fontes

    Journal of thrombosis and haemostasis

    Vol. 13, supl 2 (June, 2015), p. 842